Academic publisher Cambridge University Press has announced the launch of the 'Discovery' section within Expert Reviews in Molecular Medicine (ERMM) and now welcomes high-quality, innovative original research papers to complement its authoritative 'Reviews' section. Authors who wish to publish their papers in 'ERMM: Discovery' will be able to do so under a gold Open Access model and payment of an article processing charge (APC). Reviews will continue to be accessed via a subscription to ERMM , with Open Access as an option for Review authors to choose should they wish to pay the APC.
ERMM has been publishing high-quality peer-refereed review articles since late 1997, which have proved a valuable forum for authoritative reviews in the area of molecular medicine. The journal has an impressive Impact Factor of 6.628* (2012), which places it in a strong position amongst its competitors. This expansion will provide readers and authors with an enhanced resource for molecular medicine research.
ERMM: Discovery will be overseen and edited by Dr Julian Sale (MRC Laboratory of Molecular Biology, UK) who will be working alongside the Editor-in-Chief, Professor Timothy Cox (University of Cambridge, UK).
Molecular medicine as a broad definition refers to elucidating the pathogenesis of disease at the molecular or physiological level, which may lead to the design of specific tools for disease diagnosis, treatment or prevention - this highlights the timeliness and importance of the journal in the field. ERMM: Discovery will publish original work from across the full breadth of molecular medicine and pathology. Its scope mirrors that of ERMM: Reviews focussing on the molecular mechanisms of disease, diagnostics and therapy. The Journal particularly invites original research papers which provide mechanistic insights, while papers of a purely descriptive or correlative nature and case reports are unlikely to be accepted unless they provide exceptional scientific insight.
